Titan Pharmaceuticals, Inc. - Common Stock (TTNP)
Frequently Asked Questions About Titan Pharmaceuticals, Inc. - Common Stock (TTNP)
Has Titan Pharmaceuticals received FDA approval for its products?
Yes, Titan Pharmaceuticals has received FDA approval for Probuphine, making it the first long-acting buprenorphine product approved for the treatment of opioid dependence. This approval marked a significant milestone for the company and highlighted the potential for their innovative drug delivery technology.
How can investors learn more about Titan Pharmaceuticals?
Investors can learn more about Titan Pharmaceuticals by visiting the company's official website, where they can find information about their product pipeline, press releases, financial reports, and investor presentations. Additionally, they can follow the company’s updates on financial news platforms and participate in earnings calls.
How does Titan Pharmaceuticals prioritize patient safety?
Titan Pharmaceuticals prioritizes patient safety by adhering to rigorous regulatory standards throughout the drug development process. The company conducts comprehensive clinical trials to assess the safety and effectiveness of its therapies, ensuring that patient welfare is always at the forefront of their operations.
How has Titan Pharmaceuticals performed in the stock market?
Titan Pharmaceuticals' performance in the stock market has experienced volatility, reflecting the challenges and opportunities inherent in the biotechnology sector. Shareholder interest and stock price fluctuations are influenced by company announcements, clinical trial results, and overall market conditions.
Is Titan Pharmaceuticals publicly traded?
Yes, Titan Pharmaceuticals is publicly traded on the Nasdaq Stock Market under the ticker symbol TTNP. Being listed allows the company to raise capital through the sale of stock, enabling it to fund its research and development initiatives.
What are some challenges Titan Pharmaceuticals faces?
Like many biotechnology companies, Titan Pharmaceuticals faces challenges such as funding for ongoing research, competition from other therapeutics, and navigating complex regulatory processes. Additionally, public perception and market dynamics can also impact the company's ability to succeed in the long term.
What are the main therapeutic areas that Titan Pharmaceuticals is focused on?
Titan Pharmaceuticals primarily focuses on therapeutic areas related to addiction treatment, particularly opioid dependence, as well as chronic pain management. Their efforts are directed at developing innovative treatment options that improve patient outcomes in these challenging health domains.
What are Titan Pharmaceuticals' future plans?
Titan Pharmaceuticals plans to expand its pipeline of products by exploring additional indications for its existing technology and by developing new therapeutic candidates. The company is committed to advancing innovations in drug delivery and exploring partnerships to enhance its capabilities and reach.
What clinical trials is Titan Pharmaceuticals currently conducting?
Titan Pharmaceuticals is actively conducting clinical trials to further evaluate the efficacy and safety of its products, particularly its buprenorphine implant. The company aims to gather data to support potential new indications and enhancements to its existing therapies.
What does Titan Pharmaceuticals, Inc. do?
Titan Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing proprietary therapeutics for patients with serious medical conditions. Their primary focus is on developing long-acting medications using their unique drug delivery technology, particularly for the treatment of addiction and pain management.
What impact does Titan Pharmaceuticals aim to have on public health?
Titan Pharmaceuticals aims to have a positive impact on public health by providing effective treatment options for individuals struggling with opioid dependence and chronic pain. By developing long-acting therapies, the company seeks to enhance treatment compliance, reduce the burden of addiction, and improve overall patient quality of life.
What is Titan Pharmaceuticals' business model?
Titan Pharmaceuticals operates on a biotechnology business model centered around research and development of innovative therapies. Their model includes developing proprietary technologies, obtaining regulatory approvals, and commercializing products through partnerships and collaborations.
What is Titan Pharmaceuticals' most notable product?
Titan's most notable product is Probuphine, a subdermal implant containing buprenorphine, which is used for the treatment of opioid dependence. This innovative delivery system allows for a continuous release of medication over an extended period, significantly improving patient compliance and treatment outcomes.
What is Titan's drug delivery technology?
Titan's drug delivery technology focuses on long-acting implants that can deliver medications continuously over time. This technology minimizes the frequency of administration required by traditional oral or injectable medications, thereby enhancing patient adherence to treatment regimens.
What partnerships or collaborations does Titan Pharmaceuticals have?
Titan Pharmaceuticals seeks strategic partnerships and collaborations with other companies and organizations to enhance their research capabilities and expand their market presence. Collaborations can involve joint development agreements or partnerships for commercialization of their products.
What regulatory approvals has Titan Pharmaceuticals received?
In addition to the FDA approval for Probuphine, Titan Pharmaceuticals is committed to obtaining necessary regulatory clearances for its future product candidates. This includes working with other international regulatory bodies as they pursue global market access for their therapies.
When was Titan Pharmaceuticals founded?
Titan Pharmaceuticals was founded in 1992. Over the years, the company has focused on advancing its proprietary drug delivery systems and expanding its portfolio of therapeutic products aimed at addressing unmet medical needs in addiction treatment and chronic pain management.
Where is Titan Pharmaceuticals headquartered?
Titan Pharmaceuticals is headquartered in South San Francisco, California. This location places the company in proximity to a vibrant biotechnology community, fostering collaborations and access to resources within the industry.
Who is on Titan Pharmaceuticals' leadership team?
Titan Pharmaceuticals' leadership team comprises experienced professionals with extensive backgrounds in biotechnology, pharmaceuticals, and business development. The team includes experts in clinical development, regulatory affairs, and commercialization strategies, all working towards the company's mission.
What is the current price of Titan Pharmaceuticals, Inc. - Common Stock?
The current price of Titan Pharmaceuticals, Inc. - Common Stock is 4.610
When was Titan Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Titan Pharmaceuticals, Inc. - Common Stock was at 3:19 pm EDT on October 1st, 2025
What is the market capitalization of Titan Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Titan Pharmaceuticals, Inc. - Common Stock is 6.13M
How many shares of Titan Pharmaceuticals, Inc. - Common Stock are outstanding?
Titan Pharmaceuticals, Inc. - Common Stock has 1.33M shares outstanding.